PT-141
Also known as: Bremelanotide, Vyleesi
PT-141 (Bremelanotide) is a synthetic peptide that acts on melanocortin receptors. It was developed from the tanning peptide Melanotan II and has been studied for sexual dysfunction.
Key Findings at a Glance
- • PT-141 is the only FDA-approved peptide for sexual dysfunction, marketed as Vyleesi for treating hypoactive sexual desire disorder in premenopausal women.
- • PT-141 works through melanocortin-4 receptors in the brain rather than through vascular mechanisms, making it fundamentally different from PDE5 inhibitors like sildenafil.
- • PT-141 was originally discovered as a side effect during Melanotan II tanning research, when male subjects unexpectedly reported spontaneous erections during clinical trials.
- • Because PT-141 acts centrally on desire pathways rather than on blood flow, it is effective in populations where vascular-based treatments fail, including some forms of psychogenic dysfunction.
PT-141 Overview & Molecular Profile
PT-141 is a cyclic synthetic peptide and MC3R/MC4R agonist derived from Melanotan II by removing a carboxyl group to eliminate blood-pressure-elevating effects. FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, it is one of very few research peptides to achieve FDA approval. Its mechanism is centrally mediated via hypothalamic and limbic MC4R activation, distinct from PDE5 inhibitors like sildenafil that act peripherally on vascular smooth muscle.
Mechanism of Action: Receptor Agonism & Metabolic Pathways
PT-141 acts as an agonist at melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. These receptors are involved in sexual function and arousal. By activating these pathways, PT-141 affects sexual response through central mechanisms rather than peripheral vascular effects.
From Injection to Effect: The 2.7-Hour Peptide With 24-Hour Activity
PT-141's pharmacokinetic profile presents a striking disconnect between plasma half-life and duration of effect — a pattern seen in several neuroactive peptides where rapid receptor engagement triggers downstream signaling cascades that outlast the peptide's systemic presence.
Absorption, Distribution, and Elimination
Following subcutaneous injection of the FDA-approved 1.75 mg dose (Vyleesi), PT-141 demonstrates rapid absorption with predictable kinetics.
- • Subcutaneous Tmax is approximately 1 hour, with peak plasma concentrations reached reliably across the 1.75 mg clinical dose range.
- • Terminal elimination half-life is approximately 2.7 hours — substantially shorter than the 24-hour duration of clinical effect, indicating that receptor-mediated central signaling persists well beyond systemic peptide clearance.
- • Bioavailability following subcutaneous administration has not been published as an absolute figure in the FDA label, but the consistent dose-response relationship across Phase 3 trials confirms reliable systemic exposure from the SC route.
Clinical Dosing Constraints and the Effect-Duration Paradox
The FDA-approved prescribing information for Vyleesi includes specific pharmacokinetic-informed dosing restrictions that reflect the disconnect between half-life and duration of activity.
- • Administration is limited to no more than one dose per 24 hours and no more than 8 doses per month, despite the 2.7-hour half-life. These restrictions are based on clinical trial safety data showing that transient blood pressure increases (10-15 mmHg systolic) and nausea warrant a full 24-hour washout period between doses.
- • Onset of sexual desire effects begins within 30-60 minutes of injection — closely tracking the Tmax — but effects on desire and arousal persist for up to 24 hours, consistent with sustained MC4R signaling in hypothalamic circuits after the peptide has cleared from plasma.
- • The peptide should be administered at least 45 minutes before anticipated sexual activity. Unlike PDE5 inhibitors which require vascular arousal mechanisms, PT-141's central mechanism means the timing window is more flexible — the 24-hour effect window does not require precise timing.
PT-141 (Bremelanotide) Pharmacokinetics: Plasma Concentration vs Clinical Effect Duration
Figure: Plasma concentration (blue) peaks at approximately 1 hour and clears within 6-8 hours (t½ = 2.7h). Clinical effect on sexual desire (green dashed) persists well beyond plasma clearance, consistent with sustained MC4R signaling in hypothalamic circuits. Based on FDA-approved Vyleesi prescribing data.
Research-Observed Effects
Sexual Function Research
Extensive ResearchExtensive clinical research on PT-141 for sexual dysfunction treatment has demonstrated significant improvements in sexual desire and arousal through central melanocortin receptor activation in the hypothalamus and limbic system. Phase 3 clinical trials involving over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD) showed statistically significant increases in satisfying sexual events and reductions in distress related to low sexual desire compared to placebo groups. Unlike phosphodiesterase type 5 (PDE5) inhibitors that work through vascular mechanisms, PT-141 operates through the central nervous system, making it effective for desire-related sexual dysfunction research rather than purely mechanical arousal issues. Studies have documented onset of effects within 30-60 minutes following subcutaneous administration, with effects lasting up to 24 hours in some research subjects. These findings have positioned PT-141 as a unique research compound for investigating neural pathways involved in female sexual dysfunction treatment, male erectile dysfunction research, and understanding the neurobiological basis of sexual motivation and arousal.
Melanocortin Pathway Activation
Extensive ResearchResearch demonstrates PT-141's potent agonist activity at melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors, which are critical G-protein coupled receptors involved in regulating sexual behavior, energy homeostasis, and autonomic nervous system function. Binding studies show PT-141 has high affinity for MC4R with EC50 values in the nanomolar range, triggering intracellular signaling cascades that activate cyclic AMP and protein kinase A pathways in hypothalamic neurons. The peptide's cyclic structure, derived from its parent compound Melanotan II, provides enhanced metabolic stability and receptor selectivity compared to linear melanocortin analogs. Research into melanocortin receptor agonist mechanisms has revealed that MC4R activation in the paraventricular nucleus directly influences sexual arousal pathways independent of peripheral hormonal changes. These melanocortin pathway studies have significant implications for understanding central regulation of sexual function, appetite control mechanisms, and potential therapeutic targets for metabolic and reproductive disorders.
Central Nervous System Effects
Moderate ResearchNeuroimaging and behavioral studies indicate PT-141 produces significant central nervous system effects on motivation, reward processing, and emotional regulation through melanocortin receptor activation in limbic structures. Functional MRI research has shown increased activity in brain regions associated with sexual arousal and desire following PT-141 administration, including the anterior cingulate cortex and insula. Studies demonstrate the peptide's effects are mediated through descending neural pathways from the hypothalamus to the spinal cord, influencing both autonomic and somatic components of sexual response. Research has documented effects on dopaminergic neurotransmission, with PT-141 potentially modulating dopamine release in reward-related brain circuits. These CNS-mediated effects distinguish PT-141 from peripheral-acting sexual dysfunction treatments and have generated interest in its potential applications for research into depression-related sexual dysfunction, motivational disorders, and understanding the neuroscience of desire and reward processing.
FDA-Approved Prescribing Information
PT-141 is an FDA-approved medication. Official prescribing information is available via the NIH National Library of Medicine DailyMed database:
Approved Dosing Summary
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 1.75 mg | As needed (≥45 min before activity) | FDA-approved Vyleesi dose for HSDD in premenopausal women |
| Subcutaneous (research) | 0.5–2 mg | As needed | Range used in Phase 1–3 clinical trials |
Dosing summary above is derived from FDA-approved prescribing information. Always refer to the official drug label for complete prescribing details, contraindications, and warnings.
Research Studies & References
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women
Kingsberg SA, Clayton AH, et al.
Obstetrics & Gynecology (2019)
This pivotal Phase 3 clinical trial evaluated bremelanotide (PT-141) efficacy and safety in premenopausal women with hypoactive sexual desire disorder (HSDD), ultimately leading to FDA approval. The randomized, double-blind, placebo-controlled RECONNECT studies enrolled over 1,200 women who self-administered 1.75 mg subcutaneous injections as needed before anticipated sexual activity for 24 weeks. Results demonstrated statistically significant improvements in the Female Sexual Function Index desire domain score and meaningful reductions in distress associated with low sexual desire as measured by the Female Sexual Distress Scale. Approximately 25% of treatment subjects achieved clinically meaningful response compared to 17% with placebo, with effects observed as early as 4 weeks into treatment. The study established PT-141's unique mechanism as the first FDA-approved treatment for HSDD that works through central nervous system melanocortin pathways rather than hormonal manipulation, representing a significant advancement in sexual dysfunction research and women's health therapeutics.
Melanocortin receptor agonists, penile erection, and sexual motivation
Wessells H, Fuciarelli K, et al.
Annals of the New York Academy of Sciences (2005)
This comprehensive review and research study examined PT-141's effects on male sexual function through melanocortin receptor activation, establishing the mechanistic basis for its pro-erectile effects independent of vascular changes. Researchers demonstrated that subcutaneous PT-141 administration induced penile erection in healthy men through central nervous system pathways, with effects occurring even in the absence of sexual stimulation. The study documented dose-dependent increases in erectile response and sexual arousal scores, with optimal effects observed at doses between 4-6 mg in early clinical investigations. Neurophysiological analysis confirmed that PT-141's effects were mediated through supraspinal mechanisms rather than direct penile vascular effects, distinguishing it from PDE5 inhibitors. These findings established the foundation for understanding melanocortin-based approaches to erectile dysfunction treatment and identified PT-141 as a valuable research tool for investigating central control of male sexual function.
Central melanocortin signaling and sexual function
Van der Ploeg LH, Martin WJ, et al.
Current Opinion in Pharmacology (2002)
This foundational review synthesized early research on melanocortin receptor signaling in sexual function, providing the theoretical framework for PT-141 development as a sexual dysfunction treatment. The authors analyzed preclinical evidence demonstrating that MC3R and MC4R activation in the hypothalamus and limbic system directly influences sexual arousal, desire, and copulatory behavior in multiple species. Research presented showed that melanocortin agonists increase lordosis in female rodents and penile erection in male models through activation of oxytocinergic neurons in the paraventricular nucleus. The review highlighted the unique advantage of targeting central melanocortin pathways for addressing desire-related sexual dysfunction rather than purely mechanical arousal issues addressed by peripheral vasodilators. These mechanistic insights guided subsequent clinical development of PT-141 and established melanocortin receptors as validated therapeutic targets for sexual medicine research.
Comparative Research
Explore in-depth research analyses and comparative studies featuring PT-141.
Comparative Clinical Analysis
PT-141 vs Melanotan II: Melanocortin Peptide Comparison for Sexual Health Research | Peptpedia
PT-141 (Bremelanotide) and Melanotan II are both cyclic heptapeptide analogs of alpha-MSH acting on melanocortin receptors, but with different selectivity profiles and regulatory status. PT-141 received FDA approval in 2019 (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women—the only melanocortin peptide with this approval. Melanotan II has broader melanocortin receptor activation including MC1R (tanning) and more pronounced side effects.
Semax vs PT-141: ACTH Analog vs Melanocortin Peptide Comparison | Peptpedia
Semax and PT-141 share ACTH/alpha-MSH origin but represent pharmacologically distinct agents. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analog registered in Russia as a cognitive and neuroprotective agent; PT-141 (Bremelanotide) is an FDA-approved cyclic melanocortin peptide developed for sexual dysfunction. Both activate melanocortin receptor pathways, but with completely different clinical targets: Semax for CNS BDNF upregulation and neuroprotection; PT-141 for MC3R/MC4R-mediated sexual arousal.
Frequently Asked Questions
What is PT-141 (Bremelanotide) and how does it differ from Viagra?
PT-141 (brand name Vyleesi) is an FDA-approved cyclic peptide that activates melanocortin-3 and melanocortin-4 receptors in the hypothalamus and limbic system—the brain regions governing desire and arousal. Viagra (sildenafil) and Cialis (tadalafil) inhibit PDE5 to enhance blood flow in peripheral vascular tissue. PT-141 addresses desire (libido) through the CNS; PDE5 inhibitors address mechanical vasodilation. They operate through completely distinct mechanisms and can theoretically be complementary in cases where both desire and vascular response are impaired.
Was PT-141 actually FDA approved?
Yes. Bremelanotide (PT-141) received FDA approval in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the second FDA-approved treatment for HSDD (after flibanserin/Addyi, approved in 2015) and the only one administered subcutaneously. This approval followed two Phase 3 randomized, placebo-controlled trials involving over 1,200 women.
How does PT-141 differ from Melanotan II?
PT-141 was derived from Melanotan II by removing an amide group from the C-terminus, converting the parent cyclic structure into a metabolite that retains MC3R/MC4R activity while reducing the transient hypertension seen with Melanotan II. Both activate the same receptor pathways, but PT-141 has a more targeted pharmacological profile and has undergone full Phase 3 clinical development—unlike Melanotan II, which remains unapproved and has not been studied in large controlled trials.
What were the Phase 3 trial results for PT-141 (Vyleesi)?
Two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT studies) enrolled 1,267 premenopausal women with HSDD. At the approved 1.75 mg subcutaneous dose, participants showed statistically significant improvements in satisfying sexual events per month (+0.5 events vs. +0.2 for placebo in one trial) and meaningful reductions in distress related to low sexual desire (Female Sexual Distress Scale scores). The most common adverse events were nausea (40%), flushing (20%), and transient blood pressure increases.
Does PT-141 work in men?
Early Phase 1/2 studies examined PT-141 in men with psychogenic erectile dysfunction. Results showed significant improvement in erectile response at doses of 4–6 mg, suggesting MC3R/MC4R pathways contribute to male sexual function as well. However, PT-141 development in men was not pursued to regulatory approval—the FDA approval is specifically for premenopausal women with HSDD. Off-label research in men continues in the published literature.
What are the main side effects of PT-141?
In Phase 3 trials, the most common side effects were: nausea (40% of patients, most commonly occurring within 30 min–2 hours), facial flushing (20%), and transient increases in blood pressure (average systolic +6 mmHg). The blood pressure increase is clinically meaningful and contraindicates use in patients taking certain cardiovascular medications or with uncontrolled hypertension. Nausea was the primary reason for treatment discontinuation. The Vyleesi label includes a warning about transient focal hyperpigmentation (darkening of face, gums, or breasts) with prolonged use.
How is PT-141 (Vyleesi) dosed in the FDA-approved indication?
FDA-approved dosing for Vyleesi (PT-141/Bremelanotide) is 1.75 mg subcutaneous injection into the abdomen or thigh, administered at least 45 minutes before anticipated sexual activity. It should not be used more than once within 24 hours, and use should be limited to no more than 8 times per month. The FDA label specifically restricts use to premenopausal women with HSDD. Blood pressure should not be assessed within 12 hours of administration due to transient BP elevation. The injection device is a single-use, multi-dose auto-injector (similar to an EpiPen format in the original formulation).
What neural mechanisms explain PT-141's sexual effect?
PT-141 activates MC3R and MC4R receptors in the hypothalamus, particularly in the paraventricular nucleus (PVN) and medial preoptic area—regions central to sexual motivation and arousal. Neuroimaging research has shown that MC4R activation in the PVN triggers oxytocin release, dopamine activity in the mesolimbic system (reward circuit), and direct neural signals to the spinal cord that facilitate genital blood flow. Critically, this is a central (brain-level) mechanism—not a vascular dilation mechanism like PDE5 inhibitors (Viagra). PT-141 thus works for psychogenic desire disorders rather than purely vascular erectile dysfunction.
Related Peptides
View allRelated Comparisons
PT-141 vs Melanotan II
PT-141 (Bremelanotide) and Melanotan II are both cyclic heptapeptide analogs of alpha-MSH acting on melanocortin receptors, but with different selectivity profiles and regulatory status. PT-141 received FDA approval in 2019 (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women—the only melanocortin peptide with this approval. Melanotan II has broader melanocortin receptor activation including MC1R (tanning) and more pronounced side effects.
Semax vs PT-141
Semax and PT-141 share ACTH/alpha-MSH origin but represent pharmacologically distinct agents. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH(4-7) analog registered in Russia as a cognitive and neuroprotective agent; PT-141 (Bremelanotide) is an FDA-approved cyclic melanocortin peptide developed for sexual dysfunction. Both activate melanocortin receptor pathways, but with completely different clinical targets: Semax for CNS BDNF upregulation and neuroprotection; PT-141 for MC3R/MC4R-mediated sexual arousal.